The Roles of microRNAs in Regulating Chemotherapy Resistance of Non-Small Cell Lung Cancer

Author(s): Xiaoxuan Wei, Xiaoyan Shen, Yanchen Ren, Weidong Hu*.

Journal Name: Current Pharmaceutical Design

Volume 23 , Issue 39 , 2017

Become EABM
Become Reviewer

Abstract:

Lung cancer is considered the leading cause of cancer death in the word. Among all lung cancer cases, non-small cell lung cancer (NSCLC) accounts for 85%. Currently, chemotherapy is still the major therapeutic method of lung cancer. However, chemoresistance is a serious obstacle in treating NSCLC. Up to now, many reports have suggested that microRNAs(miRNAs) could contribute to lung cancer cell chemosensitivity. MicroRNAs, a class of endogenous non-coding small RNAs, regulate gene expression by binding to their complementary target messenger RNAs, leading to mRNA degradation or translational suppression. Numerous studies indicate that changes of specific miRNA expression may contribute to chemoresistance or chemosensitivity. Consequently, targeting specific miRNAs could become an effective approach to predict the therapeutic effect of different anticancer agents, achieve more effective personalised treatments and enhance chemosensitivity. This review summarizes the several major drug resistance mechanisms and focuses on the roles of miRNAs in regulating chemoresistance in NSCLC.

Keywords: MicroRNAs, chemotherapy, drug resistance, cisplatin, non-small cell lung cancer (NSCLC), chemosensitivity.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 23
ISSUE: 39
Year: 2017
Page: [5983 - 5988]
Pages: 6
DOI: 10.2174/1381612823666171018105207
Price: $58

Article Metrics

PDF: 26
HTML: 3